Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach
Despite the observed clinical benefits of nirmatrelvir/ritonavir (NMV/r), it is uncertain whether Taiwan will continue covering NMV/r for high-risk individuals with mild-to-moderate coronavirus disease 2019 (COVID-19). This analysis assessed the impact of sustained utilization of NMV/r on COVID-19-a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2001-6689/12/4/26 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850226976114081792 |
|---|---|
| author | Matthew Sussman Jennifer Benner Tendai Mugwagwa Jackie Lee Sheng-Tzu Hung Ya-Min Yang Yixi Chen |
| author_facet | Matthew Sussman Jennifer Benner Tendai Mugwagwa Jackie Lee Sheng-Tzu Hung Ya-Min Yang Yixi Chen |
| author_sort | Matthew Sussman |
| collection | DOAJ |
| description | Despite the observed clinical benefits of nirmatrelvir/ritonavir (NMV/r), it is uncertain whether Taiwan will continue covering NMV/r for high-risk individuals with mild-to-moderate coronavirus disease 2019 (COVID-19). This analysis assessed the impact of sustained utilization of NMV/r on COVID-19-associated healthcare resource utilization (HCRU) and mortality from the Taiwanese health authority perspective (THAP). A decision tree model estimated the incremental number of clinical events associated with NMV/r utilization over a 30-day period. Model results compared (1) a base case using current rates of NMV/r from the THAP, and (2) a hypothetical scenario assuming the current supply of NMV/r is not extended in Taiwan. NMV/r utilization rates included 80% and 0% in the base case and hypothetical scenario, respectively. Outcomes included the number of hospitalizations involving a general ward (GW) stay, intensive care unit (ICU) stay, and mechanical ventilation (MV) use, as well as the number of bed days, symptom days, and hospitalization deaths. Based on epidemiologic data, 150,255 patients with COVID-19 were eligible for treatment from the THAP. In the hypothetical scenario, HCRU increased by 175% compared to the base case, including increases in hospitalizations involving GW, ICU, and MV use (differences: 2067; 623; 591, respectively), bed days (difference: 51,521), symptom days (difference: 51,714), and deaths (difference: 480). Findings indicate that sustained utilization of NMV/r from the THAP reduces the clinical burden of mild-to-moderate COVID-19 through the reduced incidence of COVID-19-related HCRU and deaths. |
| format | Article |
| id | doaj-art-eb2624ce48814096a67ca5dc2ce4e930 |
| institution | OA Journals |
| issn | 2001-6689 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-eb2624ce48814096a67ca5dc2ce4e9302025-08-20T02:04:57ZengMDPI AGJournal of Market Access & Health Policy2001-66892024-11-0112432634110.3390/jmahp12040026Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling ApproachMatthew Sussman0Jennifer Benner1Tendai Mugwagwa2Jackie Lee3Sheng-Tzu Hung4Ya-Min Yang5Yixi Chen6Stratevi, LLC, Boston, MA 02111, USAStratevi, LLC, Boston, MA 02111, USAPfizer Ltd., Tadworth KT20 7NS, UKStratevi, LLC, Santa Monica, CA 90401, USAPfizer Inc., Taipei City 110, TaiwanPfizer Inc., Taipei City 110, TaiwanPfizer Investment Co., Ltd., Beijing 100010, ChinaDespite the observed clinical benefits of nirmatrelvir/ritonavir (NMV/r), it is uncertain whether Taiwan will continue covering NMV/r for high-risk individuals with mild-to-moderate coronavirus disease 2019 (COVID-19). This analysis assessed the impact of sustained utilization of NMV/r on COVID-19-associated healthcare resource utilization (HCRU) and mortality from the Taiwanese health authority perspective (THAP). A decision tree model estimated the incremental number of clinical events associated with NMV/r utilization over a 30-day period. Model results compared (1) a base case using current rates of NMV/r from the THAP, and (2) a hypothetical scenario assuming the current supply of NMV/r is not extended in Taiwan. NMV/r utilization rates included 80% and 0% in the base case and hypothetical scenario, respectively. Outcomes included the number of hospitalizations involving a general ward (GW) stay, intensive care unit (ICU) stay, and mechanical ventilation (MV) use, as well as the number of bed days, symptom days, and hospitalization deaths. Based on epidemiologic data, 150,255 patients with COVID-19 were eligible for treatment from the THAP. In the hypothetical scenario, HCRU increased by 175% compared to the base case, including increases in hospitalizations involving GW, ICU, and MV use (differences: 2067; 623; 591, respectively), bed days (difference: 51,521), symptom days (difference: 51,714), and deaths (difference: 480). Findings indicate that sustained utilization of NMV/r from the THAP reduces the clinical burden of mild-to-moderate COVID-19 through the reduced incidence of COVID-19-related HCRU and deaths.https://www.mdpi.com/2001-6689/12/4/26coronavirus disease 2019COVID-19nirmatrelvirnirmatrelvir/ritonavirclinical burdenmodel |
| spellingShingle | Matthew Sussman Jennifer Benner Tendai Mugwagwa Jackie Lee Sheng-Tzu Hung Ya-Min Yang Yixi Chen Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach Journal of Market Access & Health Policy coronavirus disease 2019 COVID-19 nirmatrelvir nirmatrelvir/ritonavir clinical burden model |
| title | Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach |
| title_full | Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach |
| title_fullStr | Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach |
| title_full_unstemmed | Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach |
| title_short | Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach |
| title_sort | clinical benefits of sustained oral nirmatrelvir ritonavir use for the outpatient treatment of covid 19 findings from the taiwanese health authority perspective using a decision tree modeling approach |
| topic | coronavirus disease 2019 COVID-19 nirmatrelvir nirmatrelvir/ritonavir clinical burden model |
| url | https://www.mdpi.com/2001-6689/12/4/26 |
| work_keys_str_mv | AT matthewsussman clinicalbenefitsofsustainedoralnirmatrelvirritonavirusefortheoutpatienttreatmentofcovid19findingsfromthetaiwanesehealthauthorityperspectiveusingadecisiontreemodelingapproach AT jenniferbenner clinicalbenefitsofsustainedoralnirmatrelvirritonavirusefortheoutpatienttreatmentofcovid19findingsfromthetaiwanesehealthauthorityperspectiveusingadecisiontreemodelingapproach AT tendaimugwagwa clinicalbenefitsofsustainedoralnirmatrelvirritonavirusefortheoutpatienttreatmentofcovid19findingsfromthetaiwanesehealthauthorityperspectiveusingadecisiontreemodelingapproach AT jackielee clinicalbenefitsofsustainedoralnirmatrelvirritonavirusefortheoutpatienttreatmentofcovid19findingsfromthetaiwanesehealthauthorityperspectiveusingadecisiontreemodelingapproach AT shengtzuhung clinicalbenefitsofsustainedoralnirmatrelvirritonavirusefortheoutpatienttreatmentofcovid19findingsfromthetaiwanesehealthauthorityperspectiveusingadecisiontreemodelingapproach AT yaminyang clinicalbenefitsofsustainedoralnirmatrelvirritonavirusefortheoutpatienttreatmentofcovid19findingsfromthetaiwanesehealthauthorityperspectiveusingadecisiontreemodelingapproach AT yixichen clinicalbenefitsofsustainedoralnirmatrelvirritonavirusefortheoutpatienttreatmentofcovid19findingsfromthetaiwanesehealthauthorityperspectiveusingadecisiontreemodelingapproach |